Copy to clipboard 
Results of a prospective multicenter clinical study evaluating the safety and effectiveness of Genesys Spine’s SIros Lateral Sacroiliac Joint Fusion System demonstrate significant pain reduction, functional improvement, and radiographic evidence of successful fusion, reinforcing SIros as a minimally invasive option for patients with sacroiliac joint (SIJ) dysfunction.
The study showed a 38% reduction in pain scores by six months, with the mean Numerical Rating Scale score decreasing from 6.8 at baseline to 4.2. Functional outcomes also improved significantly, while radiographic assessments revealed that 96% of patients exhibited bone apposition to both iliac and sacral sides across at least two of the three implants, and 72% showed bridging across the SI joint at six months. Importantly, there were no reports of implant failure, device migration, or procedure-related serious adverse events. Additionally, opioid use among patients declined by nearly half over the course of the study.
“The prospective study further validates SIros as a key solution for SI joint fusion,” said Meredith Gavlick, Chief Strategy Officer, SI Fusion. “Demonstrating stabilization with minimal radiation exposure and a minimally invasive approach represents a major advancement for patient outcomes and recovery.”
SIros is part of Genesys Spine’s comprehensive SI fusion portfolio, which also includes the SIrten Intra-Articular and SIros-Oi Posterior Oblique Systems. All products are intended for sacroiliac joint fusion in cases of degenerative sacroiliitis and sacroiliac joint disruption.
Source: Genesys Spine
Results of a prospective multicenter clinical study evaluating the safety and effectiveness of Genesys Spine's SIros Lateral Sacroiliac Joint Fusion System demonstrate significant pain reduction, functional improvement, and radiographic evidence of successful fusion, reinforcing SIros as a minimally invasive option for patients with sacroiliac...
Results of a prospective multicenter clinical study evaluating the safety and effectiveness of Genesys Spine’s SIros Lateral Sacroiliac Joint Fusion System demonstrate significant pain reduction, functional improvement, and radiographic evidence of successful fusion, reinforcing SIros as a minimally invasive option for patients with sacroiliac joint (SIJ) dysfunction.
The study showed a 38% reduction in pain scores by six months, with the mean Numerical Rating Scale score decreasing from 6.8 at baseline to 4.2. Functional outcomes also improved significantly, while radiographic assessments revealed that 96% of patients exhibited bone apposition to both iliac and sacral sides across at least two of the three implants, and 72% showed bridging across the SI joint at six months. Importantly, there were no reports of implant failure, device migration, or procedure-related serious adverse events. Additionally, opioid use among patients declined by nearly half over the course of the study.
“The prospective study further validates SIros as a key solution for SI joint fusion,” said Meredith Gavlick, Chief Strategy Officer, SI Fusion. “Demonstrating stabilization with minimal radiation exposure and a minimally invasive approach represents a major advancement for patient outcomes and recovery.”
SIros is part of Genesys Spine’s comprehensive SI fusion portfolio, which also includes the SIrten Intra-Articular and SIros-Oi Posterior Oblique Systems. All products are intended for sacroiliac joint fusion in cases of degenerative sacroiliitis and sacroiliac joint disruption.
Source: Genesys Spine
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
